<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41673">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563860</url>
  </required_header>
  <id_info>
    <org_study_id>3-05-117</org_study_id>
    <nct_id>NCT02563860</nct_id>
  </id_info>
  <brief_title>Pharmacological Treatment of Rett Syndrome With Statins</brief_title>
  <acronym>Statins</acronym>
  <official_title>Pharmacological Treatment of Rett Syndrome With 3-Hydroxy-3 Methylglutaryl-coenzyme A Reductase Inhibitor-Lovastatin (Mevacor)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rett Syndrome Research Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 , open label, dose escalating study of Lovastatin in Rett syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Excess neuronal cholesterol plays a role in the pathophysiology of Rett syndrome(RTT) and
      the investigators hypothesise that inhibition of cholesterol synthesis in the CNS will
      reduce neuronal cholesterol and lead to improvement in Rett syndrome related symptoms.

      Goal: To determine the optimal dosing regiment of Lovastatin for patients with RTT and to
      identify the most appropriate primary outcome measure for the subsequent Phase 3 study.

      Phase 2, dose escalation study.

      Primary outcome: Gait speed Secondary outcomes: respiratory function, cognition, EEG
      (encephalopathy), Rett syndrome severity scale, neurodevelopmental assessment (QOL)

      20 ambulatory female patients with genetically confirmed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gait velocity</measure>
    <time_frame>40 weeks</time_frame>
    <description>Measure: gait velocity. Method: computerized walkway (GAIT rite)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual attention and memory</measure>
    <time_frame>40 weeks</time_frame>
    <description>Measure:Novelty scores. Test will be performed using eyetracking technology (Tobii TX 300).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory function</measure>
    <time_frame>40 weeks</time_frame>
    <description>3 hour monitoring will be performed in polysomnography lab . Measures: breath hold index and time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Encephalopathy/EEG</measure>
    <time_frame>40 weeks</time_frame>
    <description>routine EEG will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>40 weeks</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual pursuit</measure>
    <time_frame>40 weeks</time_frame>
    <description>Measure:gain of pursuit. Test will be performed using eyetracking technology (Tobii TX 300)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Rett Syndrome</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Lovastatin, dose escalating trial according to the following schedule:
10 mg daily for 8 week 20 mg daily for 8 weeks 40 mg daily for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovastatin</intervention_name>
    <description>dose escallating</description>
    <arm_group_label>Open label</arm_group_label>
    <other_name>Mevacor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females patients,

          -  Genetically confirmed RTT,

          -  Ambulatory.

        Exclusion Criteria:

          -  Presence of co morbid non-Rett related disease,

          -  History of adverse reaction/hypersensitivity to statins,

          -  Levels of aspartate-amino trans-ferase (AST), alanine-amino transferase (ALT) or
             creatine kinase (CK) triple the normal values,

          -  Active liver disease,

          -  Concomitant use of strong CYP3A4 inhibitors,

          -  Condition predis-posing to renal failure secondary to rhabdomyolysis (scoliosis
             surgery within 6 months),

          -  Oral contraceptives use.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksandra Djukic, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 1, 2016</lastchanged_date>
  <firstreceived_date>July 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Aleksandra Djukic</investigator_full_name>
    <investigator_title>Professor of Clinical Neurology, Director, Tri State Rett Syndrome Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Rett Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>L 647318</mesh_term>
    <mesh_term>Dihydromevinolin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
